Edwards Lifesciences Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B |
| Gross profit | $4.7B | $4.3B | $4.0B | $3.7B | $4.0B |
| Operating income | $1.3B | $1.4B | $1.3B | $1.5B | $1.7B |
| Cost of revenue | $1.3B | $1.1B | $978.4M | $723.7M | $1.2B |
| Cash from operations | $1.6B | $542.3M | $895.8M | $1.2B | $1.7B |
| Capital expenditure | $260.2M | $252.4M | $253.0M | $244.6M | $325.8M |
| Free cash flow | $1.3B | $289.9M | $642.8M | $973.6M | $1.4B |
| Share repurchases | $893.4M | $1.2B | $879.6M | $1.7B | $512.8M |
| Impairments | $186.9M | $0 | $0 | $55.1M | $4.0M |
| Total assets | $13.7B | $13.1B | $9.4B | $8.3B | $8.5B |
| Total liabilities | $3.4B | $3.0B | $2.6B | $2.5B | $2.7B |
Shares outstanding 575.8M · Free float 99.7%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.